HHS is reviving a push for 340B rebate changes after an earlier pilot was blocked in court, according to a provider-focused report. Providers warned the shift would increase administrative and financial burden for already cash-strapped organizations, signaling a potential re-pricing risk across covered drug programs. The update arrives as biotech and health systems remain sensitive to reimbursement design and contract mechanics. Separately, another item noted Arkansas’ decision not to enforce Act 630 on drug distribution after a court ruling, after concerns that the law could conflict with interstate commerce principles and patient safety workflows involving REMS or special handling protocols. Together, these policy developments point to ongoing uncertainty around distribution networks and rebate execution—factors that can directly influence how quickly new therapies are available and how costs flow through the provider supply chain.